DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
DHR logo

Danaher Corporation Stock Price

NYSE:DHR Community·US$150.1b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 155 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

DHR Share Price Performance

US$206.93
3.14 (1.54%)
​
US$228.61
Fair Value
US$206.93
3.14 (1.54%)
9.5% undervalued intrinsic discount
US$228.61
Fair Value
Price US$206.93
AnalystConsensusTarget US$228.61
Thu, 23 Jul 26
Fair ValueUS$228.61
Share Pricen/a

DHR Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$228.61 9.5% undervalued intrinsic discount

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

0users have liked this narrative
0users have commented on this narrative
72users have followed this narrative
DHR logo
Danaher

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

Danaher leans on a steady stream of repeat sales from lab and diagnostic tools, helped by a growing base of customers who keep buying supplies and services. The big question is whether a gradual recovery in biotech and healthcare spending can outweigh policy swings and trade tensions—especially in Asia—that could slow orders and squeeze profits.Read more

View narrative
AN
AnalystConsensusTarget
US$228.61
9.5% undervalued intrinsic discount
AnalystConsensusTarget's
Fair Value
Revenue
8.04% p.a.
Profit Margin
21.7%
Future PE
28.12x
Price in 2029
US$290.41
View

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
DHR logo

DHR: Bioprocess Recovery And Diagnostics Expansion Will Support Premium Multiple

Fair Value: US$228.61 9.5% undervalued intrinsic discount
72 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Proven track record with mediocre balance sheet.

2 Risks
3 Rewards
View Full Analysis

Danaher Corporation Key Details

US$25.1b

Revenue

US$10.4b

Cost of Revenue

US$14.8b

Gross Profit

US$10.8b

Other Expenses

US$4.0b

Earnings

Last Reported Earnings
Jun 26, 2026
Next Reporting Earnings
n/a
5.68
58.75%
15.89%
50.5%
View Full Analysis

About DHR

Founded
1969
Employees
59000
CEO
Rainer Blair
WebsiteView website
www.danaher.com

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Recent DHR News & Updates

Recent updates

No updates

Danaher Corporation Competitors

LLY logo

Eli Lilly

Symbol: NYSE:LLY
Market cap: US$1.0t
JNJ logo

Johnson & Johnson

Symbol: NYSE:JNJ
Market cap: US$640.7b
ABBV logo

AbbVie

Symbol: NYSE:ABBV
Market cap: US$453.1b
MRK logo

Merck

Symbol: NYSE:MRK
Market cap: US$364.5b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide